0G8X Stock Chart & Stats
kr0.17
>-kr0.01(-5.27%)
At close: 4:00 PM EDT
kr0.17
>-kr0.01(-5.27%)
Day’s Range― - ―
52-Week Rangekr0.06 - kr0.34
Previous CloseN/A
Volume17.50K
Average Volume (3M)81.63K
Market Cap
kr50.92M
Enterprise Valuekr99.54M
Total Cash (Recent Filing)kr34.90M
Total Debt (Recent Filing)kr3.27M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 05, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding672,666,900
10 Day Avg. Volume163,257
30 Day Avg. Volume81,630
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)kr3.00M
Bulls Say, Bears Say
Bulls Say
Clinical ValidationStrong sensitivity and specificity in a symptomatic high-risk subgroup support the test’s clinical credibility and its Medicare submission. If further studies confirm these results, the evidence base can strengthen physician confidence, payer discussions, and adoption over the next several quarters.
Commercial Adoption PipelineUse across 27 surveillance programs and ordering by major cancer centers provide evidence of real-world commercial traction. Expansion from 71 to more than 110 engaged centers creates a broader conversion opportunity and could support recurring test volume as workflows mature.
Low Financial LeverageLow debt and modest debt-to-equity reduce the burden of mandatory interest and principal payments compared with a highly leveraged model. This gives Immunovia greater balance-sheet flexibility while it develops clinical evidence, pursues coverage, and seeks to scale commercialization.
Bears Say
Severe Operating LossesThe revenue base remains far too small to absorb the company’s operating cost structure, producing deeply negative gross profit and substantial net losses. Unless commercial growth materially outpaces spending, persistent losses will continue to erode equity and delay a credible path to breakeven.
Cash Burn And Financing NeedHeavy cash outflows relative to the company’s current scale create a durable funding constraint. Management expects existing cash to last only into Q4 2026 and is evaluating financing or partnerships, so future execution depends partly on securing capital before runway expires.
Reimbursement And Adoption UncertaintyUncertain reimbursement rates and Medicare timing make future revenue conversion difficult to forecast, even with clinical and center-level interest. Restricted coverage for symptomatic high-risk patients may limit the addressable population, while workflow changes can slow repeat ordering and broader adoption.
Immunovia AB News
0G8X FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest share price was kr0.06 and its highest was kr0.34 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is kr50.92M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Nov 05, 2026 which is in 22 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Aug 06, 2026. The company reported -kr0.03 earnings per share for the quarter, beating the consensus estimate of -kr0.04 by kr0.01.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is -0.02.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -kr0.03 in its last earnings report, beating expectations of -kr0.04. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in GB:0G8X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
0G8X Company Deck
0G8X Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of meaningful commercial and clinical progress alongside material operational and financing risks. Key positives include very strong percentage revenue growth, robust clinical performance (83.3% sensitivity, ~92% specificity), major center uptake, and an expanding engaged pipeline. Offsetting these are still-modest absolute revenues, an increased operating loss due to higher personnel and study spending, limited cash runway into Q4 2026 requiring near-term financing or partnerships, and uncertainty around reimbursement levels and timing. Overall, the company is showing clear early commercial and clinical traction but remains exposed to execution and funding risks as it scales.View all GB:0G8X earnings summariesTechnical Analysis
Biosergen AB
―
Q-linea AB
―
Acarix AB
―
Biovica International AB Class B
―
Devyser Diagnostics AB
―